Our news
NeoPhore appoints Dr Matthew Baker as VP Immunology
08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker a…
Neophore's SAB member publishes article on JCO Precision Oncology
Dr. Luis Diaz, Neophore’s Scientific Advisory Member and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital has r…
NeoPhore appoints Dr John Haurum as Non-Executive Director
Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…
NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme
Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…
Other news
BioCentury's Emerging Company Profile
CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
‘Big place’ for small-molecule booster drugs in cancer immunotherapy, says NeoPhore CEO
APM Health: Interview with CEO, Jeff Roix
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…